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Coagulation monitoring: current techniques and clinical use of
viscoelastic point-of-care coagulation devices
Abstract
Perioperative monitoring of blood coagulation is critical to better understand causes of hemorrhage, to
guide hemostatic therapies, and to predict the risk of bleeding during the consecutive anesthetic or
surgical procedures. Point-of-care (POC) coagulation monitoring devices assessing the viscoelastic
properties of whole blood, i.e., thrombelastography, rotation thrombelastometry, and Sonoclot analysis,
may overcome several limitations of routine coagulation tests in the perioperative setting. The advantage
of these techniques is that they have the potential to measure the clotting process, starting with fibrin
formation and continue through to clot retraction and fibrinolysis at the bedside, with minimal delays.
Furthermore, the coagulation status of patients is assessed in whole blood, allowing the plasmatic
coagulation system to interact with platelets and red cells, and thereby providing useful additional
information on platelet function. Viscoelastic POC coagulation devices are increasingly being used in
clinical practice, especially in the management of patients undergoing cardiac and liver surgery.
Furthermore, they provide useful information in a large variety of clinical scenarios, e.g., massive
hemorrhage, assessment of hypo- and hypercoagulable states, guiding pro- and anticoagulant therapies,
and in diagnosing of a surgical bleeding. A surgical etiology of bleeding has to be considered when
viscoelastic test results are normal. In summary, viscoelastic POC coagulation devices may help identify
the cause of bleeding and guide pro- and anticoagulant therapies. To ensure optimal accuracy and
performance, standardized procedures for blood sampling and handling, strict quality controls and
trained personnel are required.
Coagulation Monitoring: 
Current Techniques and Clinical Use of  
Viscoelastic Point of Care Coagulation Devices 
 
Michael T. Ganter MD* and Christoph K. Hofer MD# 
 
 
*  Assistant Professor; Department of Anesthesia and Perioperative Care 
University of California San Francisco, San Francisco CA 
 
#  Senior Consultant; Institute of Anesthesiology and Intensive Care Medicine 
Triemli City Hospital Zurich, Switzerland 
 
 
 
 
 
Short Title: Viscoelastic bed-side coagulation devices. 
 
 
Corresponding Author: Christoph K Hofer, MD 
Institute of Anesthesiology and Intensive Care Medicine, Triemli City Hospital Zurich,  
Birmensdorferstr. 497 ,8063 Zurich, Switzerland  
Phone: +41 44 466 22 09, Fax: +41 44 466 27 43 
Email: christoph.hofer@triemli.stzh.ch 
 
 
Financial Support, Conflict of Interest: This review was written without any financial 
support from manufacturers or the pharmaceutical industries. None of the authors is related to 
or has financial interests in any of the companies or manufacturers of products related to this 
study.  
 1
Implication Statement 
Viscoelastic point of care coagulation devices are increasingly being used in clinical 
practice to assess the patient’s coagulation status in whole blood, letting the coagulation 
system interact with platelets and red cells. The advantage of these techniques is they have the 
potential to measure the clotting process with minimal time delays from fibrin formation 
through clot retraction and fibrinolysis. 
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Abstract 
Perioperative monitoring of blood coagulation is critical to better understand causes of 
hemorrhage, to guide hemostatic therapies and to predict the risk of bleeding during the 
consecutive anesthetic or surgical procedures.  Point of care (POC) coagulation monitoring 
devices assessing the viscoelastic properties of whole blood, i.e. thrombelastography (TEG®), 
rotation thrombelastometry (ROTEM®) and Sonoclot® analysis may overcome several 
limitations of routine coagulation tests in the perioperative setting. The advantage of these 
techniques is they have the potential to measure the clotting process starting with fibrin 
formation and continue through to clot retraction and fibrinolysis at the bed-side with minimal 
time delays. Furthermore, the coagulation status of patients is assessed in whole blood letting 
the plasmatic coagulation system interact with platelets and red cells thereby providing useful 
additional information on platelet function.  Viscoelastic POC coagulation devices are 
increasingly being used in clinical practice, especially in the management of patients 
undergoing cardiac and liver surgery. Furthermore, they provide useful information in a large 
variety of clinical scenarios, e.g., massive hemorrhage, assessment of hypo- and 
hypercoagulable states, guiding pro- and anti-coagulant therapies and in diagnosing of a 
surgical bleeding. A surgical etiology of bleeding has to be considered when viscoelastic test 
results are normal. In summary, viscoelastic POC coagulation devices may help identify the 
cause of bleeding and guide pro- and anti-coagulant therapies. To ensure optimal accuracy and 
performance, standardized procedures for blood sampling and handling, strict quality controls 
and trained personnel are required.  
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Introduction 
Perioperative monitoring of coagulation is important to diagnose potential causes of 
hemorrhage, to guide hemostatic therapies, and to predict the risk of bleeding during the 
consecutive surgical procedures (1). Most commonly, routine laboratory based coagulation 
tests (e.g., PT/INR, aPTT, fibrinogen) and platelet numbers are being used to assess the 
patients’ current coagulation status.  However, the value of these tests has been questioned in 
the acute perioperative setting (2) because there are delays from blood sampling to obtaining 
results (45-60 min), coagulation tests are determined in plasma rather than whole blood, no 
information is available on platelet function and the assays are performed at a standard 
temperature of 37ºC rather than the patients’ temperature. 
Point of care (POC) coagulation monitoring devices assessing the viscoelastic properties of 
whole blood, i.e. thrombelastography (TEG®), rotation thrombelastometry (ROTEM®) and 
Sonoclot® analysis may overcome several limitations of routine coagulation tests (3,4). Blood 
is analyzed at the bed-side and not necessarily in the central laboratory allowing faster 
turnaround times. The coagulation status is assessed in whole blood, allowing in vivo 
coagulation system interactions with platelets and red blood cells to provide useful information 
on platelet function. Furthermore, the clot development can be visually displayed in real-time 
and the coagulation analysis can be done at the patients’ temperature. However, there is still a 
big difference between in vitro and in vivo coagulation that has to be considered: viscoelastic 
coagulation tests measure the coagulation status under static conditions (no flow) in a cuvette 
(not an endothelialized blood vessel). Therefore, results obtained from these in vitro tests have 
to be carefully interpreted after considering the clinical conditions (e.g., overt bleeding in the 
surgical site). 
The aim of this article is to review the basic principles of the current viscoelastic POC 
coagulation analyzers, to outline their clinical use, and to evaluate their ability to monitor 
different pharmacological substances interacting with hemostasis in the perioperative setting. 
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Viscoelastic POC devices have also been used for coagulation testing of certain hemostatic 
disorders or syndromes in the hemostasis laboratory, but will not be discussed in this review. 
Thrombelastography, Thrombelastometry 
Thrombelastography was first described by Hartert in 1948 as a method to assess the global 
hemostatic function from a single blood sample (5). In the earlier literature, the terms 
thrombelastography, thrombelastograph and TEG have been used generically. However, in 
1996 thrombelastograph® and TEG® became registered trademarks of the Haemoscope 
Corporation (Niles, IL, USA) and from that time on these terms have been employed to 
describe the assay performed using Haemoscope instrumentation only. Alternatively, 
Pentapharm GmbH (Munich, Germany) markets a modified instrumentation using the 
terminology rotation thrombelastometry, ROTEM® (3).  
The TEG/ROTEM® assess the viscoelastic properties of blood samples under low shear 
conditions. The TEG® (Figure 1A) measures the clots’ physical property by using a stationary 
cylindrical cup that holds the blood sample and oscillates through an angle of 4°45’. Each 
rotation cycle lasts 10 seconds. A pin is suspended in the blood by a torsion wire and is 
monitored for motion (Figure 2A). The torque of the rotation cup is transmitted to the 
immersed pin only after fibrin-platelet bonding has linked the cup and pin together. The 
strength of these fibrin-platelet bonds affects the magnitude of the pin motion. Thus, the output 
is directly related to the strength of the formed clot. As the clot retracts or lyses, these bonds 
are broken and the transfer of cup motion is again diminished. The rotation movement of the 
pin is converted by a mechanical-electrical transducer to an electrical signal finally being 
displayed as the typical TEG® tracing (Figure 3A). The ROTEM® instrument (Figure 1B) uses 
a modified technology: signal transmission of the pin suspended in the blood sample is carried 
out via an optical detector system, not a torsion wire and the movement is initiated from the 
pin, not the cup (Figure 2B) (6). Furthermore, the instrument is equipped with an electronic 
pipette. 
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TEG/ROTEM® both measure and graphically display the changes in viscoelasticity at all 
stages of the developing and resolving clot, i.e. the time until initial fibrin formation (TEG® 
reaction time [R]; ROTEM® clotting time [CT]), the kinetics of fibrin formation and clot 
development (TEG® kinetics [K], alpha angle [α]; ROTEM® clot formation time [CFT], alpha 
angle [α]), the ultimate strength and stability of the fibrin clot (TEG® maximum amplitude 
[MA]; ROTEM® maximum clot firmness [MCF]) and clot lysis (fibrinolysis) (Table 2A) 
(7,8). TEG/ROTEM® are fibrinolysis sensitive assays and allow for diagnosis of 
hyperfibrinolysis in bleeding patients (3,9). In our manuscript, the variables from the 
TEG/ROTEM® will be referred to as they respectively relate to each instrument, for example 
R/CT or MA/MCF. 
Commercially available tests for both technologies are listed in Table 1. Typically, blood 
samples are activated extrinsically (tissue factor) and/or intrinsically (contact activator). 
Furthermore, to determine fibrinogen levels, tests in presence of a platelet inhibitor (e.g., 
cytochalasin D in fib-TEM) should be performed. This modified MA/MCF then represents the 
fibrin clot that developed in absence of any platelets, i.e. the functional fibrinogen (6,10). It has 
been shown that the MA/MCF of these modified tests correlated well with the fibrinogen 
assessed by the Clauss method (r = 0.85 [TEG® 5000 User Manual] and r = 0.75 (11)). The 
traditional Clauss method however, determines fibrinogen levels indirectly: Excess thrombin is 
added to diluted plasma, the time is measured until a clot develops and fibrinogen is calculated 
with the help of a calibration curve. Although the Clauss method is considered a standard 
assay, it has been demonstrated that hemodilution with colloids may interfere with this assays 
reporting falsely high levels of fibrinogen (12). 
Although TEG® and ROTEM® tracings look similar (Figure 3A), the nomenclature and 
reference ranges are different (Table 2A) (13). The differences may be explained by different 
cups and pins used in both systems (ROTEM® cups and pins are composed of a plastic with 
greater surface charge resulting in greater contact activation compared to cups and pins used in 
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TEG®) and different proprietary formulas of the coagulation activators (composition, 
concentrations) (13). For example, if the same blood specimen is analyzed by TEG® and 
ROTEM® with their proprietary intrinsic coagulation activator, i.e. kaolin and in-TEM (partial 
thromboplastin phospholipids), respectively, the results obtained with both systems are 
significantly different: A recent study by Nielsen et al showed that the CT was nearly three-
fold shorter than the R time and that the α-angle was 7% greater in the ROTEM® compared to 
the TEG®. It is therefore critical that care is taken when practicing with TEG® and ROTEM® 
systems, especially if the clinician utilizes a treatment algorithm created with one system (e.g., 
TEG®) while analyzing patient samples with the other system (e.g., ROTEM®) (13). The 
repeatability of measurements by both devices is acceptable (summarized in Table 2B), 
provided they are performed exactly as outlined in the users’ manuals [TEG® 5000 User 
Manual] (6). 
Sonoclot Analysis 
The Sonoclot® Analyzer (Figure 1C, Sonoclot® Coagulation & Platelet Function 
Analyzer, Sienco Inc., Arvada, CO) has been introduced in 1975 by von Kaulla et al (14). The 
principle of the Sonoclot® analysis has been described recently in detail (4). Briefly, the 
Sonoclot® measurements are based on the detection of viscoelastic changes of a whole blood 
or plasma sample. To start a measurement, a hollow, open ended disposable plastic probe is 
mounted on the transducer head. Then, the test sample is added to the cuvette containing 
different coagulation activators / inhibitors. After an automated mixing procedure, the probe is 
immersed into the sample and oscillates vertically in the sample. The changes in impedance to 
movement imposed by the developing clot are measured (Figure 2C). Different cuvettes with 
different coagulation activators / inhibitors are commercially available (Table 1). Normal 
values for the Sonoclot® Analyzer are shown in Table 3. 
The Sonoclot® Analyzer provides information on the entire hemostasis process both in a 
qualitative graph, known as the Sonoclot® Signature (Figure 3C) and as quantitative results: 
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the activated clotting time (ACT), the clot rate and the platelet function. The ACT is the time 
from the activation of the sample until the beginning of a fibrin formation. This onset of clot 
formation is defined as an upward deflection of the Sonoclot® Signature. Sonoclots' ACT 
corresponds to the conventional ACT measurement, provided that cuvettes containing a high 
concentration of a typical activators (celite, kaolin) are being used (15-18). How can we 
compare R/CT of TEG/ROTEM® to the ACT determined by Sonoclot®? The rotation of the pin 
of the TEG/ROTEM® begins to be impaired after fibrin-platelet bonding has linked the cup 
and pin together. Thus, the output is directly related to the strength of the formed clot. The 
output of Sonoclots’ oscillating plastic probe, however, is sensitive to viscosity and monitors 
viscosity changes that occur during initiation of coagulation and clot development. Therefore, 
the ACT rather reflects initial fibrin formation and R/CT rather reflect a more developed and 
later occurring stage of initial clot formation. This theoretical claim is being supported by a 
recent study by Tanaka et al (19): Simultaneously, ACT and R values were determined in 
kaolin activated whole blood samples. R values of TEG® were 1.5 fold (native blood 
samples), 3.9 fold (heparinized samples) or 4.2 fold (bivalirudin treated samples) higher 
compared to ACT values determined by Sonoclot®.  
Besides providing information on the initiation phase of coagulation, the Sonoclot® 
Analyzer also measures the kinetics of fibrin formation and clot development, expressed as 
clot rate (CR; the maximum slope of the Sonoclot® Signature during initial fibrin 
polymerization and clot development). Furthermore, the function of the platelets is being 
analyzed and reported as platelet function (PF; derived from the timing and quality of the clot 
retraction). The nominal range of values for the PF goes from 0, representing no PF (no clot 
retraction and flat Sonoclot® Signature after fibrin formation), to approximately 5, 
representing strong PF (clot retraction occurs sooner and is very strong, with clearly defined, 
sharp peaks in the Sonoclot® Signature after fibrin formation) (see manufacturer’s reference) 
(20). 
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The Sonoclot® Analyzer has been criticized because its results were influenced by age, 
sex, and platelet count (21). Additionally, studies showed poor reproducibility of some of the 
measured parameters, especially CR and PF (22,23). However, others found the Sonoclot® 
Analyzer to be valuable and reliable in patients undergoing cardiac surgical procedures (24,25) 
and the Sonoclot® Analyzer has even demonstrated a precision close to that of 
thrombelastography (26). In more recent studies, test variability of ACT values determined by 
Sonoclot® were comparable to other established ACT analyzers (8-9% on average) (15-18). 
Furthermore, test variability for PF determined by gbACT+ and H-gbACT+ (heparinase glass-
bead test) was 6-10% in a recent study assessing PF after administration of the glycoprotein 
IIb/IIIa (GPIIb/IIIa) antagonist tirofiban with or without heparin (20).  
Cardiac Surgery and Postoperative Care 
Coagulation management of patients undergoing cardiac surgery is complex because of a 
balance between anticoagulation for cardiopulmonary bypass (CPB) and hemostasis after CPB. 
Furthermore, an increasing number of patients have impaired platelet function at baseline due 
to administration of anti-platelet agents. During CPB, optimal anticoagulation dictates that 
coagulation is antagonized and platelets are prevented from activation so that clots do not 
form. After surgery, coagulation abnormalities, platelet dysfunction, and fibrinolysis can occur, 
creating a situation whereby hemostatic integrity must be restored. The complex process of 
anticoagulation with heparin, antagonism with protamine, and postoperative hemostasis 
therapy can be guided by point-of-care tests that assess hemostatic function in a timely and 
accurate manner (1). 
Although studies report that viscoelastic POC coagulation devices may predict excessive 
bleeding after CPB, findings are not consistent and evidence supporting its usefulness as a 
predictor of bleeding is minimal (27-29). Normal viscoelastic test results in a leading patient is 
unlikely due to a significant coagulopathy (high negative predictive value) (30). Therefore, 
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viscoelastic POC tests may be useful in early identification and targeted treatment of a surgical 
bleeding. 
The institution of transfusion algorithms based on TEG/ROTEM® parameters has been 
demonstrated to reduce transfusion requirements in adults and children undergoing cardiac 
surgery (31-35). Furthermore, it has been recently shown that implementation of ROTEM® 
guided coagulation management is cost-effective (33). To detect non-heparin related 
hemostatic problems in presence of large amounts of heparin, tests with heparinase have been 
developed (Table 1) and a recent study showed that implementation of an algorithm based 
upon heparinase-modified TEG® resulted in a significant reduction of transfusion blood 
products (36).  
POC coagulation analyzers measuring ACT are routinely being used in cardiac surgical 
patients to guide heparin induced anticoagulation and its reversal (37-40). Besides standard 
ACT machines, viscoelastic POC analyzers also provide ACT results with comparable 
accuracy and performance. The ACT provided by the Sonoclot® Analyzer is being used to 
guide heparin therapy and several tests with different characteristics are commercially 
available (Table 1) (15-17). More recently, a novel assay has also been developed to measure 
ACT by TEG® (41).  
Hepatic Surgery and Postoperative Care 
Patients undergoing hepatic surgery and particularly orthotopic liver transplantation (OLT) 
may have large derangement in their coagulation making POC coagulation monitoring highly 
desirable. Problems associated with the defective organ (decreased synthesis and clearance of 
clotting factors, platelet defects) lead to impaired hemostasis and hyperfibrinolysis. 
Furthermore, systemic complications like sepsis and disseminated intravascular coagulation 
(DIC) further complicate a pre-existing coagulopathy. Finally, marked changes in hemostasis 
in OLT occur during the anhepatic phase and immediately following organ reperfusion, mainly 
a hyperfibrinolysis resulting from accumulation of tissue plasminogen activator due to 
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inadequate hepatic clearance and a release of exogenous heparin and endogenous heparin-like 
substances. 
One of the first clinical applications of TEG® was in the hemostatic management of OLT 
(42). Although the value of TEG/ROTEM® in management of patients undergoing OLT has 
been established in the literature (11,43,44), only a third of all OLT programs in the United 
States routinely used viscoelastic coagulation devices according to a national survey in 2002 
(45). In addition to the hemorrhagic risk associated with hepatic surgery and OLT, 
hypercoagulability and thrombotic complication have been described in the postoperative 
period and can be adequately assessed with TEG/ROTEM® (46,47). Only few studies are 
available on the use of the Sonoclot® Analyzer in hepatic surgery and OLT, however, this 
technique has also been found to be useful in the perioperative coagulation management of 
these patients (48,49).  
Hypercoagulability, Thrombosis and Other Clinical Situations 
Recognized risk factors for thrombosis are generally related to one or more elements of 
Virchow’s triad (stasis, vessel injury, and hypercoagulability) (50). Major surgery has been 
shown to induce a hypercoagulable state in the postoperative period and this 
hypercoagulability has been implicated in the pathogenesis of postoperative thrombotic 
complications, including deep vein thrombosis (DVT), pulmonary embolism (PE), myocardial 
infarction (MI), ischemic stroke, and vascular graft thrombosis (51,52).  
Identifying hypercoagulability with conventional non-viscoelastic laboratory tests is 
difficult unless the fibrinogen concentration or platelet count is markedly increased. However, 
hypercoagulability is readily being diagnosed by viscoelastic POC coagulation analyzers and 
TEG/ROTEM® (only few data exist on the use of Sonoclot®) have been increasingly used in 
the assessment of postoperative hypercoagulability for a variety of surgical procedures (51,53-
55). Hypercoagulability is being diagnosed if the R/CT time is short and the MA/MCF is 
increased (exceeding 65-70 mm) (7,51). 
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Viscoelastic techniques have been used to assess blood coagulation in multiple clinical 
situations besides the assessment of hypercoagulability and outside the cardiac and hepatic 
units, but large experience is limited. For example, TEG® has been successfully applied to 
assess the coagulation status in trauma patients (55,56). Finally, there is a long list of 
publications on the successful use of TEG/ROTEM® and Sonoclot® in other clinical areas, 
summarized in recent reviews (3,4,57).  
Monitoring anticoagulation 
ACT measurements to guide heparin therapy and the use of modified POC coagulation 
tests with heparinase to assess the coagulation status in absence of the anti-coagulatory effects 
of heparin have been described above. However, besides the monitoring of unfractioned 
heparin, studies have shown that treatment with low molecular weight heparin (LMWH) and 
heparinoids (e.g. danaparoid) can also be assessed with POC viscoelastic tests (58). Both, 
standard and heparinase-modified tests have to be performed in order to increase the sensitivity 
of TEG/ROTEM® for the effects of LMWH and heparinoids. 
Direct thrombin inhibitors are increasingly being used for prevention and treatment of 
venous thromboembolic events, management of patients with acute coronary syndromes and 
percutaneous coronary interventions and anticoagulation in patients with heparin induced 
thrombocytopenia (59). POC viscoelastic techniques, especially the ecarin clotting time (ecarin 
directly activates thrombin) have been shown to be helpful in the assessment of the hemostasis 
system in patients treated with direct thrombin inhibitors (60,61). 
Monitoring Anti-Platelet Therapy / Platelet Function 
In Western countries, anti-platelet therapy is increasingly being prescribed for primary and 
secondary prevention of cardiovascular disease to decrease the incidence of acute cerebro- and 
cardiovascular events. Anti-platelet agents typically target to inhibit cycloxygenase 1 / 
ThromboxaneA2 (TxA2) receptors (e.g., aspirin), ADP receptors (e.g., clopidogrel) or 
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GPIIb/IIIa receptors (e.g., abciximab, tirofiban). Although anti-platelet agents are thought to 
work primarily by decreasing platelet aggregation, they also have been shown to function as 
anticoagulants: Activated platelets facilitate thrombin generation by providing a catalytic cell 
surface on which coagulation reactions may occur and they release activated Factor V. Vice 
versa, anticoagulants may also alter platelet function (62,63). Because platelets play a key role 
in overall coagulation, the assessment of the platelet function (more than their number) is 
critical in the perioperative setting (64,65).  
Traditional assays, such as turbidimetric platelet aggregometry, are still considered a 
clinical standard for platelet function testing. However, conventional platelet aggregometry is 
labor intensive, costly, time consuming, and requires a high degree of experience and expertise 
to perform and interpret. Furthermore, platelets are tested under relatively low shear conditions 
in platelet rich plasma, conditions that do not accurately simulate primary hemostasis (65). 
Viscoelastic POC coagulation analyzers may provide information on platelet function but 
these tests also assess coagulation under low shear conditions. The MA/MCF from 
TEG/ROTEM® reflect overall platelet function and fibrinogen levels. It is recommended to 
run two different tests simultaneously, e.g. ex-TEM (tissue factor activated test) and fib-TEM 
(ex-TEM plus cytochalasin D to inhibit platelet function): The difference between clot 
firmness of ex-TEM and fib-TEM then represents the platelet contribution. However, since 
conventional TEG/ROTEM® are not sensitive to targeted pharmacological inhibition, a more 
sophisticated test has been recently developed for the TEG® to specifically determine platelet 
function in presence of anti-platelet therapy (PlateletMapping™) (66,67). Briefly, the maximal 
hemostatic activity of the blood specimen is first measured by a kaolin activated whole blood 
sample. Then, further measurements are performed in presence of heparin to eliminate 
thrombin activity: Reptilase and Factor XIII (Activator F) generate a cross-linked fibrin clot to 
isolate the fibrin contribution to the clot strength. The contribution of the ADP or TxA2 
receptors to the clot formation is provided by the addition of the appropriate agonists, ADP or 
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arachidonic acid. The results from these different tests are then compared to each other and the 
platelet function calculated (68).  
The Sonoclot® Analyzer has also been shown to reliably detect pharmacological 
GPIIb/IIIa inhibition (20,69). To obtain reliable results for PF, cuvettes containing glass beads 
for specific platelet activation (gbACT+) should be used (20).  
Monitoring Pro-Coagulant Therapy  
Modern practice of coagulation management is based on the concept of specific component 
therapy and requires rapid diagnosis and monitoring of the pro-coagulant therapy. It has been 
shown for example that platelet transfusion in the perioperative period of CABG is associated 
with increased risk for serious adverse events (70). Clinical judgment alone or combined with 
conventional non-viscoelastic laboratory tests cannot predict who will benefit from a platelet 
transfusion in the acute perioperative setting. Therefore, the most recent guidelines on 
perioperative blood transfusion and blood conservation of the societies of thoracic surgeons 
(STS) and cardiovascular anesthesiologists (SCA) clearly state that transfusion of coagulation 
products should be preferably guided by point-of-care tests that assess hemostatic function in a 
timely and accurate manner (1).  
Fibrinogen is a key coagulation factor (substrate to form a clot) and isolated fibrinogen 
substitution in severe models of dilutional coagulopathy has been shown to improve clot 
strength and reduce blood loss (71). Supplementary administration of prothrombin complex 
(concentrate of factor II, VII, IX, X, antithrombin III, protein C) additionally improved 
initiation of coagulation and reversed the dilutional coagulopathy (72). As mentioned earlier in 
this review, fibrinogen levels can be assessed by measuring clot strength (MCF/MA) in 
presence of platelet inhibition (e.g., fib-TEM) (11) or by assessing Sonoclot’s CR (73).  
Recombinant activated factor VII (rVIIa) treatment is currently approved for patients with 
congenital or acquired hemophilia with antibodies to Factor VIII or IX (United States and 
Europe), factor VII deficiency and Glanzmanns thrombasthenia (Europe). However, rVIIa is 
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increasingly used in off-label indications to control severe bleeding (e.g., major trauma, 
surgical interventions, intracerebral hemorrhage) in theory by locally activating hemostasis at 
sites of vascular injury. The resulting thrombin burst then leads to the formation of a fibrin 
clot, sufficient fibrinogen levels provided. Consensus guidelines have been published for these 
off-label indications, but it is still unclear how to reliably monitor patients receiving rVIIa 
(74,75). To better study the result of thrombin generation (i.e., fibrin polymerization, factor 
XIII activation, factor XIIIa crosslinking of fibrin polymers and platelet activation), modified 
TEG/ROTEM® parameters based on the first derivative of original TEG/ROTEM® tracing 
have been introduced recently: maximum velocity of clot formation (maximum rate of 
thrombus generation, MaxVel), time to reach MaxVel (time to maximum thrombus generation, 
tMaxVel) and total thrombus generation (area under the curve, TTG) (76-78). These 
parameters are supposed to be more sensitive to rVIIa than standard TEG/ROTEM® 
parameters and dilute tissue factor should be used as coagulation activator for best sensitivity 
(57). In a preliminary study, we were able to monitor the effects of rVIIa in vitro after severe 
hemodilution using the new diluted tissue factor activated tests from ROTEM® (tif-TEM) and 
Sonoclot® (microPT) (73,79). 
Factor XIII is needed for cross-linking fibrin therefore stabilizing the clot, increasing clot 
strength and resistance to fibrinolysis. There are case reports on patients with unexplained 
intraoperative bleeding due to decreased factor XIII and subsequent stabilization after 
substitution. Impaired clot strength and increased lysis have been observed (80). 
Antifibrinolytic drugs (aprotinin, tranexamic and epsilon aminocaproic acid) are used 
mostly in cardiac surgery to reduce bleeding and transfusion requirements. Aprotinin may 
interact with POC coagulation assays, prolonging for example celite activated ACT tests. 
Therefore, kaolin or aprotinin-insensitive ACT should be used to guide heparin therapy in 
these patients (16,17). Antifibrinolytic therapy may be predicted in vitro in TEG/ROTEM® 
with certain tests already containing an antifibrinolytic agent (e.g., ap-TEM). Ap-TEM 
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predictive for a good patient response would then show a significantly improved 
initiation/propagation phase compared to ex-TEM and or disappearance of signs of 
hyperfibrinolysis. There are no conclusive studies on monitoring desmopressin (DDAVP) 
therapy so far. 
Critiques of Point of Care Coagulation Monitoring 
Several concerns have been raised using viscoelastic POC coagulation tests because these 
tests are hard to standardize. The blood collection site, processing of the sample (native vs. 
citrated samples, time delay between collection and measurement – for citrated samples a 
minimum rest time of 30 min is required) patient age and gender may significantly affect the 
results of these tests (3). Furthermore, equipment, activators and other modifications will alter 
the assay specificity. All these factors have to be considered interpreting results in the literature 
and have to be known and standardized when running tests in a single center. 
As with all POC devices, there is a concern that the devices are not adequately maintained, 
supervised and that quality controls are not done on a regular basis. Furthermore, non-
laboratory personnel are running these POC tests, which may lead to further errors, if not 
adequately trained (TEG® and Sonoclot® have been listed as a moderate complexity tests by 
the Clinical Laboratory Improvement Amendment, CLIA). Alternatively, to minimize these 
problems and release the OR / ICU personnel, the so-called POC coagulation analyzers have 
been recently moved into the central laboratory in some hospitals thereby no longer being 
located at the bed-side – a trained person runs the viscoelastic coagulation test and the results 
(evolving signatures) are submitted real-time to the patient’s site.  
 
Conclusions 
Viscoelastic POC coagulation analyzers are being used in certain clinical situations known 
for their inherent risk of coagulation disorders, especially in the management of patients 
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undergoing cardiac and liver surgery. Furthermore, they provide useful information in a large 
variety of clinical scenarios, e.g., massive hemorrhage, assessment of hypo- and 
hypercoagulable states and monitoring of pharmacological treatment with anti- and pro-
coagulant agents. The advantage of these techniques is that they have the potential to measure 
the entire clotting process starting with fibrin formation and continue through to clot retraction 
and lysis at the bed-side with minimal time delays. Although physiological clot development is 
better depicted as a result of whole blood analysis of the coagulation status, these techniques 
measure hemostasis under static conditions in vitro and the results of these tests have to be 
carefully interpreted correlating them to the current clinical condition. Finally, to bring 
viscoelastic POC coagulation analyzers to the next level in the future, several improvements 
like easier handling of blood samples, full automation, simultaneous testing with multiple 
activators, integrated analyzing software, and high robustness of the devices would be highly 
desirable. 
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Legends to Tables and Figures 
Table 1 
Title:   Commercially available tests for viscoelastic point of care coagulation devices. 
Footnote:  ACT = activated clotting time, TF = tissue factor, ADP = adenosine diposphate, 
GPIIb/IIIa = glycoprotein IIb/IIIa receptor. * For research use only (not yet on the 
market by 2007). 
Table 2A 
Title:  Nomenclature and reference values of Thrombelastography (TEG®) and 
Thrombelastometry (ROTEM®). 
Footnote:  TEG®: N = normal values for kaolin activated TEG® in native whole blood 
(WB) or citrated and recalcified blood samples (Cit) [Haemoscope Corp.]. 
ROTEM®: N = normal values for contact (partial thromboplastin phospholipids, 
in-TEM), tissue factor (ex-TEM) and tissue factor plus platelet inhibitor 
cytochalasin D (fib-TEM) activated citrated and recalcified blood samples (6). 
Reference values depend on reference population, blood sampling technique, 
other pre-analytical factors and coagulation activator. 
Table 2B 
Title:  Coefficient of variation for Thrombelastography (TEG®) and 
Thrombelastometry (ROTEM®). 
Footnote:  TEG®: values are given for kaolin activated blood samples [Haemoscope Corp.].  
ROTEM®: values are given for contact (in-TEM) and tissue factor (ex-TEM) 
activated blood samples (6). For abbreviations see Table 2A. 
Table 3 
Title:  Reference values for Sonoclot® tests. 
Footnote:  Values are given for native whole blood [Sienco Inc.]. For specific details on 
assays, see Table 1. 
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 Figure 1 
Title:   Viscoelastic point of care coagulation devices.  
Footnote A. Thrombelastograph, TEG® (Haemoscope Corp., Niles, IL). B. Rotation 
Thrombelastometry, ROTEM® (Pentapharm GmbH, Munich, Germany). C. 
Sonoclot® Analyzer (Sienco Inc., Arvada, CO). 
 
Figure 2 
Title:   Working principles of viscoelastic point of care coagulation devices. 
Footnote:  A. TEG®: rotating cup with blood sample (1), coagulation activator (2), pin and 
torsion wire (3), electromechanical transducer (4), data processing (5). B. 
ROTEM®: Cuvette with blood (1), activator added by pipetting (2), pin and 
rotating axis (3), electromechanical signal detection via light source and mirror 
mounted on axis (4), data processing (5). C. Sonoclot®: Blood sample in cuvette 
(1) containing activator (2), disposable plastic probe (3) oscillating in blood 
sample mounted on electromechanical transducer head (4), data processing (5).  
 
Figure 3 
Title:   Typical tracings of viscoelastic point of care coagulation devices. 
Footnote:  A, upper side. TEG® tracing: R = reaction time, K = kinetics, α = slope between 
r and k, MA = maximum amplitude, CL = clot lysis. A, lower side. ROTEM® 
tracing: CT = clotting time, CFT = clot formation time, α = slope of tangent at 2 
mm amplitude, MCF = maximal clot firmness, LY = Lysis. B. Sonoclot® 
Signature: ACT = activated clotting time, CR = clot rate, PF = platelet function. 
For detailed description and reference values see Table 2A and 3A. 
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Table 1 
 
 
Assay Activator 
Inhibitor 
Proposed indication 
Thrombelastograph Hemostasis System (TEG®) 
Kaolin Kaolin Overall coagulation assessment and platelet function 
 
Heparinase Kaolin  
+ Heparinase 
Specific detection of heparin (modified Kaolin test 
adding heparinase to inactivate present heparin) 
Platelet Mapping ADP 
Arachidonic acid 
Platelet function, monitoring antiplatelet therapy 
(aspirin, ADP-, GPIIb/IIIa inhibitors) 
Native None Non-activated assay 
Also used to run custom hemostasis tests 
Rotation Thrombelastometry (ROTEM®) 
ex-TEM TF Extrinsic pathway; fast assessment of clot formation 
and fibrinolysis 
in-TEM Contact activator  Intrinsic pathway; assessment of clot formation and 
fibrin polymerisation 
fib-TEM TF + platelet 
antagonist 
Qualitative assessment of fibrinogen levels 
ap-TEM TF  
+ Aprotinin 
Fibrinolytic pathway; fast detection of fibrinolysis 
when used together with ex-TEM 
hep-TEM Contact activator 
+ Heparinase 
Specific detection of heparin (modified in-TEM test 
adding heparinase to inactivate present heparin) 
eca-TEM Ecarin Management of direct thrombin inhibitors (e.g., 
hirudin, argatroban) 
tif-TEM* 1:1000 TF Extrinsic pathway; monitoring recombinant activated 
factor VIIa 
na-TEM None Non-activated assay 
Also used to run custom hemostasis tests  
Sonoclot® Coagulation and Platelet Function Analyzer 
SonACT Celite High dose heparin management without aprotinin 
 
kACT Kaolin High dose heparin management with / without 
aprotinin 
aiACT Celite  
+ Clay 
High dose heparin management with aprotinin 
(aprotinin-insensitive ACT) 
gbACT+ Glass beads Overall coagulation and platelet function assessment 
 
H-gbACT+ Glass beads  
+ Heparinase 
Overall coagulation and platelet function assessment 
in presence of heparin; detection of heparin 
microPT* 1:1000 TF Extrinsic pathway; monitoring recombinant activated 
factor VIIa 
Native None Non-activated assay 
Also used to run custom hemostasis tests  
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Table 2A 
 
 TEG® ROTEM® 
   
Clotting time 
(period to 2 mm 
amplitude) 
 
R (reaction time) 
N (WB) 4-8 min 
N (Cit, kaolin) 3-8 min 
CT (clotting time) 
N (Cit, in-TEM) 137-246 sec 
N (Cit, ex-TEM) 42-74 sec 
 
Clot kinetics 
(period from 2 to 20 mm 
amplitude) 
K (kinetics) 
N (WB) 1-4 min 
N (Cit, kaolin) 1-3 min 
CFT (clot formation time) 
N (Cit, in-TEM) 40-100sec 
N (Cit, ex-TEM) 46-148 sec 
 
Clot strengthening  
(alpha angle) 
 
α (slope between r and k) 
N (WB) 47-74° 
N (Cit, kaolin) 55-78° 
α (slope of tangent at 2mm amplitude) 
N (Cit, in-TEM) 71-82° 
N (Cit, ex-TEM) 63-81° 
 
Amplitude (at set time) 
 
A  A  
Maximum strength  
 
MA (maximum amplitude) 
N (WB) 55-73 mm 
N (Cit, kaolin) 51-69 mm 
MCF (maximum clot firmness) 
N (Cit, in-TEM) 52-72 mm 
N (Cit, ex-TEM) 49-71 mm 
N (Cit, fib-TEM) 9-25 mm 
 
Lysis (at fixed time) 
 
CL30, CL60 LY30, LY60 
 
 
Table 2B 
 
Coefficient of variation 
 TEG® (kaolin activated) ROTEM® (in-, ex-TEM) 
   
Clotting time 
 
R = 13% CT = 3-12% 
 
Clot kinetics K = 4% CFT 3-12% 
 
Clot strengthening  α = 3% α =1-5% 
 
Maximum strength  MA =6% MCF = 1-5% 
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Table 3 
 
Sonoclot® Assay SonACT  kACT gbACT+ aiACT 
     
Activated clotting time 
(ACT) 
85-145 sec 94-178 sec 119-195 sec 62-93 sec 
Clot_Rate                         15-45 Units/min 15-33 Units/min 7-23 Units/min 22-41Units/min 
(CR)  Clot Signal  
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